Supplementary Tables 1 and 2 and Supplementary Figures 1 and 2 from A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic &lt;i&gt;BRAF&lt;/i&gt;-Mutant Colorectal Cancer